Rocket Pharmaceuticals, Inc. (RCKT) Balance Sheet
As of 2026-06-30 (10-Q), Rocket Pharmaceuticals, Inc. (RCKT) reported total assets of $423.1M, total liabilities of $54.3M and shareholders' equity of $368.8M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $224.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RCKTRocket Pharmaceuticals, Inc.Follow RCKT — free
—
Price chart with a free account
- Market cap
- 251.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 80.0 | 29.8 | 18.1 | 111.4 | 185.4 | 297.1 | 232.7 | 140.5 | 55.9 | 163.6 | 77.6 | 224.5 | |
| Short-term investments | 31.2 | 96.7 | 0.0 | 94.4 | 118.7 | 185.6 | 156.0 | 215.9 | 317.3 | 208.7 | 111.4 | 59.2 | |
| Current assets | 112.4 | 128.3 | 19.0 | 209.1 | 307.8 | 487.3 | 392.1 | 364.1 | 378.2 | 378.2 | 192.7 | 289.6 | |
| Total assets | 113.3 | 129.6 | 20.1 | 251.3 | 372.1 | 590.8 | 497.0 | 551.8 | 566.3 | 527.7 | 330.4 | 423.1 | |
| Current liabilities | 4.1 | 7.0 | 4.5 | 15.4 | 18.3 | 32.6 | 22.2 | 39.2 | 48.5 | 40.7 | 30.2 | 31.3 | |
| Short-term debt | — | — | — | — | 0.0 | 4.9 | 0.0 | — | — | — | — | — | |
| Total liabilities | 4.5 | 56.5 | 4.6 | 57.3 | 64.8 | 87.3 | 42.3 | 62.1 | 73.8 | 64.5 | 53.2 | 54.3 | |
| Shareholders' equity | 15.5 | 8.4 | 15.5 | 194.0 | 307.3 | 503.5 | 454.7 | 489.7 | 492.6 | 463.2 | 277.2 | 368.8 |
USD millions · SEC XBRL
Rocket Pharmaceuticals, Inc. — questions
- How much cash does Rocket Pharmaceuticals, Inc. have?
- $224.5M in cash and cash equivalents as of 2026-06-30.
- What are Rocket Pharmaceuticals, Inc.'s total assets?
- $423.1M as of 2026-06-30.
- What is Rocket Pharmaceuticals, Inc.'s shareholders' equity?
- $368.8M as of 2026-06-30.
Every figure on this page comes from Rocket Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.